AGTC to Host Second Quarter Financial Results Conference Call and Webcast on February 11, 2021

Rhea-AI Summary

Applied Genetic Technologies Corporation (Nasdaq: AGTC) will announce financial results for the fiscal quarter ending December 31, 2020, on February 11, 2021, before market opens. A conference call is scheduled for the same day at 8:00 AM ET to discuss the results and provide updates. AGTC focuses on gene therapies for rare diseases, with clinical trials for X-linked retinitis pigmentosa and achromatopsia. The company aims to address significant unmet clinical needs using its advanced AAV technology.

Positive

• AGTC is positioned as a leader in gene therapy for rare diseases.
• Active clinical programs are addressing significant unmet medical needs.

Negative

• No financial data or performance metrics provided in the PR.

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that it will report financial results for the fiscal quarter ended December 31, 2020 before the market opens on Thursday, February 11, 2021. AGTC management will host a conference call beginning at 8:00 AM Eastern Time on the same date to review results and provide a corporate update.

To access the call, dial 877-407-6184 (US) or 201-389-0877 (outside of the US). A live webcast will be available in the Events and Presentations section of the Investor Relations page at http://ir.agtc.com/events-and-presentations. Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the company's website.

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 & ACHM CNGA3). Its preclinical programs build on the Company’s industry-leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

IR/PR CONTACTS: 
David Carey (IR) or Glenn Silver (PR)
Lazar FINN Partners
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com

Corporate Contact:
Bill Sullivan
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5728
bsullivan@agtc.com

Stephen Potter
Chief Business Officer
Applied Genetic Technologies Corporation
T: (617) 413-2754
spotter@agtc.com

FAQ

When will AGTC report its financial results for Q1 2021?

AGTC will report its financial results for the fiscal quarter ended December 31, 2020, on February 11, 2021.

What time is the AGTC conference call scheduled for?

The AGTC conference call is scheduled for 8:00 AM Eastern Time on February 11, 2021.

What are the key clinical programs AGTC is working on?

AGTC is conducting clinical trials for X-linked retinitis pigmentosa and achromatopsia.